Loading content
Dr Huiqin Yang

Dr Huiqin Yang

Senior Research Fellow in Health Technology Assessment

6008

South Cloisters 

Dr Huiqin Yang joined the Peninsula Technology Assessment Group (PenTAG) from the Centre for Reviews and Dissemination at the University of York. She is a Senior Research Fellow at PenTAG, with over ten years research experience in Health Services Research. She has undertaken a range of Health Technology Assessment (HTA) projects for the National Institute for Health and Clinical Excellence (NICE) and the National Institute for Health Research (NIHR) HTA Programme, including multiple and single therapeutic technology appraisals, diagnostic imaging technology and prognostic technology assessments in several clinical areas. These areas include advanced breast cancer, osteoporosis, scoliosis, psoriasis, obesity and psoriatic arthritis.

Dr Yang has a PhD in Medical Decision Making and an MSc. in Evidence Based Practice (Health Services Research) from the University of York. She has published a number of original papers that contribute to the methodological development of medical decision making research.

Dr Yang is Deputy Director of Peninsula Technology Assessment Group at the University of Exeter Medical School (UEMS). She is responsible for the leadership and management of the systematic review team at PenTAG, the health technology assessment group at UEMS.  

Dr Yang is an Associate Editor of BMC Health Services Research. She is a member of the Cochrane Bias Methods Group, the Cochrane Prognosis Methods Group, the Cochrane Individual Participant Data Meta-analysis Methods Group, and the European Society for Medical Decision Making.

Broad research specialisms:                              

  • Health Technology Assessments
  • Systematic Reviews and Meta-analysis
  • Medical Decision Making
  • Diagnostic Accuracy
  • Health Services Research

Qualifications

  • PhD in Medical Decision Making (University of York)
  • MSc in Evidence-based Practice: Health Services Research (University of York)

Research

Research interests

Huiqin’s research interests include health technology assessments, medical decision making, diagnostic/prognostic ability of tests, biomarkers and decision aid technologies, the use of mixed treatment comparisons in health technology assessments, individual patient data meta-analysis, statistical modeling, systematic review methodology, signal detection analysis, calibration analysis, judgement analysis, diagnostic reasoning and accuracy, and research implementation.

Research projects

  • Nivoumab for treating previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. Technology Appraisal commissioned by National Institute for Health and Clinical Excellence (NICE); London: NIHR HTA, 2017 

 

  • The clinical and cost-effectiveness of lung cancer screening by low dose CT. Technology assessment report commissioned by the NIHR HTA Programme on behalf of the National Screening Committee; London: NIHR HTA, 2017

     

  • High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Technology appraisal report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence; London: NIHR HTA, 2016

 

  • Eliglustat for treating type 1 Gaucher disease: Technology Appraisal report commissioned by National Institute for Health and Clinical Excellence (NICE); London: NIHR HTA, 2016

 

  • The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Technology assessment report commissioned by the NIHR HTA Programme; London: NIHR HTA, 2015 

 

  • Bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high risk groups. Technology assessment report commissioned by the NIHR HTA Programme; London: NIHR HTA, 2014. 

 

  • Systematic review and economic evaluation of EOS 2D/3D X-ray imaging system. Technology appraisal report commissioned by National Institute for Health and Clinical Excellence (NICE); London: NIHR HTA, 2012.

 

  • Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Technology appraisal report commissioned by National Institute for Health and Clinical Excellence (NICE); London: NIHR HTA, 2011. 

 

  • Golimumab for the treatment of psoriatic arthritis. Technology appraisal report commissioned by National Institute for Health and Clinical Excellence (NICE); London: NIHR HTA, 2010.

 

  • Bevacizumab in combination with taxanes for the treatment of HER2-negative 1st line metastatic breast cancer. Technology appraisal report commissioned by National Institute for Health and Clinical Excellence (NICE); London: NIHR HTA, 2010. 

Committee/panel activities

  • Member of the Cochrane Bias Methods Group
  • Member of the Cochrane Individual Participant Data Meta-analysis Methods Group
  • Member of the Cochrane Prognosis Methods Group
  • Member of the European Society for Medical Decision Making.

Editorial responsibilities

  • Associate Editor of the BMC Health Services Research

 

  • Editorial Board Member for the BMC Health Services Research 

Invited lectures

  • Invited speaker - ‘Do we know more than we think we do: Investigating calibration in healthcare professionals’ clinical judgements and decisions.’ Departmental ‘SpotlightOn’ Research Seminar, Faculty of Medicine and Healthcare, the University of Leeds, UK. February 2016.          

Back | Edit Profile